Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 3700 Records) |
Query Trace: Lung Neoplasms and EGFR[original query] |
---|
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis. The clinical respiratory journal 2024 4 18 (4): e13748. Liuxian Guo, Guojin Zhou, Min Huang, Kejing Tang, Jing Xu, Jie Ch |
Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis. JCO global oncology 2024 4 10 e2300379. Thomas Knapp, Joseph Nygaard, Joshua Cassinat, Fernando Galvez, Priya K Gopal |
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer. Journal of translational medicine 2024 4 22 (1): 326. Wei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, Zhi-Hong Chen, Yi-Chen Zhang, Ming-Yi Yang, Jia-Qi Liu, Jing-Yan Xu, Xiao-Rong Yang, Ri-Wei Zhong, Li-Bo Tang, Lin-Xi Yin, Yu Deng, Ying-Long Peng, Chang Lu, Bao-Long Chen, Dong-Xian Ke, Hai-Yan Tu, Jin-Ji Yang, Chong-Rui Xu, Yi-Long Wu, Qing Zh |
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 2024 4 15 41-47. Danielle Brazel, Misako Nagasa |
Incidental detection of ground glass nodules and primary lung cancer in patients with breast cancer: prevalence and long-term follow-up on chest computed tomography. Journal of thoracic disease 2024 4 16 (3): 1804-1814. Hye Sun Ryu, Han Na Lee, Jung Im Kim, Jung Kyu Ryu, Yu Jin L |
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Targeted oncology 2024 4 . Naoya Nishioka, Hisao Imai, Masahiro Endo, Akifumi Notsu, Kosei Doshita, Satoshi Igawa, Hiroshi Yokouchi, Takashi Ninomiya, Takaaki Tokito, Sayo Soda, Takasato Fujiwara, Tetsuhiko Asao, Shinji Nakamichi, Takahisa Kawamura, Minehiko Inomata, Kazuhisa Nakashima, Kentaro Ito, Yasuhiro Goto, Yukihiro Umeda, Soichi Hirai, Ryota Ushio, Keiki Yokoo, Takayuki Takeda, Tomoya Fukui, Masashi Ishihara, Takashi Osaki, Sousuke Kubo, Takumi Fujiwara, Chie Yamamoto, Takeshi Tsuda, Nobumasa Tamura, Shinobu Hosokawa, Yusuke Chihara, Satoshi Ikeda, Naoki Furuya, Yoshiro Nakahara, Satoru Miura, Hiroaki Okamo |
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort. Cancers 2024 4 16 (7): . Rossella Bruno, Anello Marcello Poma, Martina Panozzi, Alessandra Lenzini, Gianmarco Elia, Carmelina Cristina Zirafa, Vittorio Aprile, Marcello Carlo Ambrogi, Editta Baldini, Marco Lucchi, Franca Melfi, Antonio Chella, Andrea Sbrana, Greta A |
Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art. Cancers 2024 4 16 (7): . Federico Pio Fabrizio, Ilaria Attili, Filippo de Marin |
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer. Lung cancer (Amsterdam, Netherlands) 2024 4 191 107540. Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, Futoshi Kurimoto, Taiki Hakozaki, Kakeru Hisakane, Tomoyuki Naito, Satoshi Takahashi, Namiko Taniuchi, Chika Yajima, Yukio Hosomi, Takashi Hirose, Yuji Minegishi, Tetsuya Okano, Koichiro Kamio, Tomoyoshi Yamaguchi, Masahiro Seike, |
Case report: Efficacy of icotinib treatment in lung adenocarcinoma with esophageal squamous cell carcinoma: a rare case of double primary malignant tumors. Frontiers in medicine 2024 4 11 1266062. Min Deng, Xiaoqing Li, Honghao Mu, Man Wei, Lan S |
Habitat-Based Radiomics for Predicting EGFR Mutations in Exon 19 and 21 From Brain Metastasis. Academic radiology 2024 4 . Chunna Yang, Ying Fan, Dan Zhao, Zekun Wang, Xiaoyu Wang, Huan Wang, Yanjun Hu, Lingzi He, Jin Zhang, Yan Wang, Yan Liu, Xianzheng Sha, Juan |
Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 2 . Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F Smit, Lodewyk F A Wessels, Edwin Cuppen, Joachim G J V Aerts, Emile E Voe |
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience. Cancer research and treatment 2024 1 . So Heun Lee, Hyehyun Jeong, Deok Hoon Kim, Se Jin Jang, Sang-We Kim, Shinkyo Yoon, Dae Ho L |
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science 2024 1 . Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizu |
PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center. Journal of the Egyptian National Cancer Institute 2024 1 36 (1): 3. Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ghanashyam Bisw |
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors. The journal of pathology. Clinical research 2024 1 10 (2): e354. Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Michael Allgäuer, Christin Assmann, Johannes Schnorbach, Anna-Lena Volckmar, Timothy Kwang Yong Tay, Hannah Goldschmid, Daniel Sw Tan, Michael Thomas, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger, Petros Christopoul |
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal transduction and targeted therapy 2024 1 9 (1): 23. Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Likun Chen, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fa |
Efficacy and safety of 40?mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study. Thoracic cancer 2024 1 . Ayumu Otsuki, Naoki Inoshima, Kentaro Tochigi, Hiroyuki Ito, Kei Nakashi |
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer 2024 1 . Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Ya |
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis. Lung cancer (Amsterdam, Netherlands) 2024 1 188 107475. Haicheng Wu, Qian Zhang, Wanchen Zhai, Yunfei Chen, Yehao Yang, Mingning Xie, Zhiyu Huang, Yanjun Xu, Hui Li, Lei Gong, Sizhe Yu, Yun Fan, Kaiyan Ch |
Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib. Pharmaceutics 2024 1 16 (1): . Jian Liu, Swan Lin, Anthony Huynh, Weiwei T |
Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study. BMC cancer 2024 1 24 (1): 117. Jing Qian, Zelai He, Ying Wu, Hongwei Li, Qun Zhang, Xianming |
Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiaoxu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xueding Wang, Li Zha |
The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma. Journal of cancer research and therapeutics 2024 1 . Mukremin Uysal, Ismail Beypinar, Murat Ar |
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC. Therapeutic advances in medical oncology 2024 1 16 17588359231222604. Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Ya |
Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study. Journal of personalized medicine 2024 1 14 (1): . Hidekazu Tanaka, Masako Karita, Kazushi Ueda, Taiki Ono, Miki Kajima, Yuki Manabe, Koya Fujimoto, Yuki Yuasa, Takehiro Shiino |
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 1 JCO2301017. Tony Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Ya |
Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study. Journal of thoracic disease 2024 1 15 (12): 7013-7023. Yalei Zhang, Yan Hao, Hui Pan, Hongbo Zheng, Jiaqi Zh |
Genomic profiling of relapsed small cell lung cancer reveals potential pathways of therapeutic targets. Journal of thoracic disease 2024 1 15 (12): 6796-6805. Wen Ouyang, Jing Yu, Zihang Zeng, Jun Gong, Junhong Zhang, Conghua X |
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study. Respiratory investigation 2024 1 62 (2): 262-268. Taisuke Araki, Shintaro Kanda, Miho Obara, Toshihiko Agatsuma, Yumiko Kakizaki, Mineyuki Hama, Hiroshi Yamamoto, Munetake Takada, Manabu Yamamoto, Akemi Matsuo, Daichi Kondo, Masamichi Komatsu, Kei Sonehara, Kazunari Tateishi, Masayuki Hanaoka, Tomonobu Koizu |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: